Compare AbbVie Inc (ABBV) vs KeyCorp (KEY) Price & Performance

AbbVie (ABBV) trades at $246.04, up 0.89% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, projected at $64.4B for 2026, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Key products Skyrizi and Rinvoq are driving growth, offsetting Humira declines, while recent news highlights promising Phase 2 data for ELAHERE in ovarian cancer.

The outlook is positive, supported by a $281.33 average price target and 71% buy ratings, but risks include high debt levels, patent cliffs in the 2030s, and margin pressure. Dividend growth remains a strength, with a recent increase of 5.48%. Investors should weigh the strong product pipeline against execution risks and valuation metrics like a P/E of 70.05.

KeyCorp (KEY) trades at $22.73, up 0.31% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.41. Recent Q2 2026 earnings beat estimates with EPS of $0.44, driven by net interest income growth and fee expansion. The acquisition of Clearwater UK bolsters its investment banking presence, while a 3.6% dividend yield adds income appeal.

Outlook is positive with earnings momentum and strategic acquisitions supporting growth, but risks include interest rate sensitivity and competitive pressures. Wall Street sentiment is bullish with 61% buy ratings, though net cash flow volatility and modest ROE of 2.72% warrant caution for value-focused investors.